1.9 USD
+0.05 (+2.7%)
1.94 USD
+0.04 (+2.11%)
We assign a fundamental rating of 2 out of 10 to LIFE. LIFE was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of LIFE have multiple concerns. LIFE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LIFE had negative earnings in the past year.
LIFE had a negative operating cash flow in the past year.
In the past 5 years LIFE always reported negative net income.
In the past 5 years LIFE always reported negative operating cash flow.
1.2 Ratios
LIFE's Return On Assets of -47.62% is in line compared to the rest of the industry. LIFE outperforms 49.74% of its industry peers.
Looking at the Return On Equity, with a value of -63.85%, LIFE is in line with its industry, outperforming 58.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.62% | ||
| ROE | -63.85% | ||
| ROIC | N/A |
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LIFE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LIFE has more shares outstanding
Compared to 5 years ago, LIFE has more shares outstanding
Compared to 1 year ago, LIFE has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.12, we must say that LIFE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.12, LIFE is doing worse than 61.18% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that LIFE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, LIFE is in line with its industry, outperforming 44.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.12 |
ROIC/WACCN/A
WACC8.87%
2.3 Liquidity
LIFE has a Current Ratio of 6.07. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LIFE (6.07) is better than 60.66% of its industry peers.
A Quick Ratio of 6.07 indicates that LIFE has no problem at all paying its short term obligations.
The Quick ratio of LIFE (6.07) is better than 61.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.07 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 37.93% over the past year.
LIFE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -94.34%.
LIFE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -67.68% yearly.
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 35.04% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 291.57% on average over the next years. This is a very strong growth
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
LIFE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIFE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LIFE's earnings are expected to grow with 26.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.08%
EPS Next 3Y26.27%
5. Dividend
5.1 Amount
LIFE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.9
+0.05 (+2.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners69.81%
Inst Owner Change-8.02%
Ins Owners12.06%
Ins Owner Change0%
Market Cap129.87M
Revenue(TTM)588.00K
Net Income(TTM)-53.93M
Analysts81.82
Price Target25.09 (1220.53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.74%
Min EPS beat(2)-2.98%
Max EPS beat(2)4.45%
EPS beat(4)3
Avg EPS beat(4)9.32%
Min EPS beat(4)-2.98%
Max EPS beat(4)22.57%
EPS beat(8)6
Avg EPS beat(8)12.77%
EPS beat(12)7
Avg EPS beat(12)6.02%
EPS beat(16)10
Avg EPS beat(16)4.78%
Revenue beat(2)1
Avg Revenue beat(2)475.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)1051.96%
Revenue beat(4)1
Avg Revenue beat(4)193.76%
Min Revenue beat(4)-100%
Max Revenue beat(4)1051.96%
Revenue beat(8)2
Avg Revenue beat(8)641.07%
Revenue beat(12)2
Avg Revenue beat(12)394.04%
Revenue beat(16)4
Avg Revenue beat(16)382.04%
PT rev (1m)8.85%
PT rev (3m)10.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.98%
EPS NY rev (1m)2.81%
EPS NY rev (3m)-7.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-84.63%
Revenue NY rev (3m)-95.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 220.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.54 | ||
| P/tB | 1.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.01
BVpS1.24
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.62% | ||
| ROE | -63.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 432.17% | ||
| Cap/Sales | 507.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.07 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | -4.12 |
F-Score1
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)486.58%
Cap/Depr(5y)301.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%
EBIT growth 1Y-25.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.85%
EBIT Next 3Y43.39%
EBIT Next 5Y48.12%
FCF growth 1Y-54.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.21%
OCF growth 3YN/A
OCF growth 5YN/A
ATYR PHARMA INC / LIFE FAQ
What is the ChartMill fundamental rating of ATYR PHARMA INC (LIFE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LIFE.
What is the valuation status for LIFE stock?
ChartMill assigns a valuation rating of 1 / 10 to ATYR PHARMA INC (LIFE). This can be considered as Overvalued.
How profitable is ATYR PHARMA INC (LIFE) stock?
ATYR PHARMA INC (LIFE) has a profitability rating of 1 / 10.
Can you provide the financial health for LIFE stock?
The financial health rating of ATYR PHARMA INC (LIFE) is 3 / 10.